Application of USP1 inhibitor in preparation of medicine for enhancing STING-mediated anti-tumor immunity

By using USP1 inhibitors to enhance the activation of STING signaling pathway, the problem of obstruction of type I interferon release in the tumor microenvironment after radiotherapy was solved, significantly improving the anti-tumor immune response, especially in 'cold tumor', which significantly improved the therapeutic effect. .

CN118903428AActive Publication Date: 2024-11-08THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411032336.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-08
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

After radiotherapy, the STING signaling pathway is disabled in the tumor microenvironment, resulting in the blockage of type I interferon release and inhibition of immune response, making it difficult to trigger an anti-tumor immune response, especially in 'cold tumors' treatment effect is not good.

Method used

By using USP1 inhibitors, such as ML323, SJB2-043, small-molecular compounds such as ML323 and SJB2-043, the USP1 activity is inhibited, the activation of STING signaling pathway is enhanced, the release of type I interferon is promoted, and the anti-tumor immune effect is enhanced.

Benefits of technology

It significantly improves the immune effect of tumor treatment after radiotherapy, enhances the STING-mediated anti-tumor immune response, provides a stable distancing effect, especially in 'cold tumors', which significantly improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903428A_ABST
    Figure CN118903428A_ABST
Patent Text Reader

Abstract

The invention relates to an application of a USP1 inhibitor in preparation of a medicine for enhancing STING-mediated anti-tumor immunity. A large number of researches find that the response of DC and other immune cells to dsDNA can be greatly enhanced by inhibiting deubiquitination enzyme USP 1, the activation degree of STIN G-mediated I-type interferon pathway is effectively improved, it is clear that USP1 hinders the transfer process of STING from endoplasmic reticulum to Golgi apparatus through deubiquitination regulation and control, activation of STING is limited, and the activity of Golgi apparatus is improved. Therefore, the effect of activating an STING pathway in a tumor by means of an STING direct agonist or chemoradiotherapy and the like is insufficient, and the anti-tumor effect is limited. The invention discloses the action mechanism of the USP1 and the mechanism of breaking through hindering factors, and evaluates the important effect of the USP1 inhibitor on enhancing STING-mediated anti-tumor immunity after radiotherapy, thereby providing a necessary and solid foundation for radiotherapy treatment schemes with innovative action mechanisms and research and development of tumor immune drugs, providing sufficient scientific basis for realizing clinical transformation, and having broad application prospects. The method has important scientific significance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to the use of USP1 inhibitors in the preparation of drugs that enhance STING-mediated anti-tumor immunity. Background Art

[0002] Radiotherapy (RT) for tumors is a treatment method that uses high-energy radiation to damage the DNA of tumor cells and kill them. It is an effective treatment method for controlling and ablating solid tumors in clinical practice. According to incomplete statistics, about 70% of patients with malignant tumors need to receive radiotherapy at different stages of their treatment, and more than 50% of tumor patients receive radiotherapy and benefit. Therefore, radiotherapy occupies an extremely important position in the treatment of malignant tumors, especially in the treatment of nasopharyngeal carcinoma, early laryngeal cancer, cervical cancer, breast cancer and rectal cancer. Radiotherapy can achieve the effect of preserving function, improving survival rate and even curing that other therapies cannot achieve. In recent years, the technological innovation of tumor radiotherapy has been changing with each passing day. In addition to breakthroughs in new technologies and treatment plans for directional radiation delivery such as three-dimensional conformal radiotherapy (3D-CRT), important progress has also been made in the research on the mechanism and effect of radiotherapy damage.

[0003] The X (or gamma) rays used in radiotherapy are ionizing radiation rays. These high-energy rays have wave-particle duality and can interact with other atoms or molecules (mainly water molecules) in cells to produce free radicals. These free radicals can diffuse a certain distance to reach and damage key target DNA. It can be seen that DNA damage is the main biological effect of ionizing radiation. In addition, the large number of free radicals (such as reactive oxygen free radicals) produced in cells also provide important conditions for the initiation of other cell programmed death methods.

[0004] It is worth noting that the effects of radiotherapy are not limited to direct killing of tumor cells. Recent studies have shown that irradiated cells, as the source of cytokine or damage-associated molecules (DAMPs) secretion, have a regulatory effect on the remodeling of the tumor microenvironment or systemic immune response, which may be a decisive factor in the effectiveness of radiotherapy or the duration of efficacy (recurrence). However, in clinical practice, the immune response caused by radiotherapy is generally at a low level, especially the abscopal effect is difficult to observe, which means that the efficiency of triggering systemic immune response by local irradiation is insufficient. The reason is that due to the intrinsic characteristics and self-regulation of tumor tissues and tumor cells, the key stage of radiotherapy-induced immune response is inhibited in most cases. In the analysis of immunosuppressive factors after radiotherapy, combined with the research results in the prior art, it was found that radiation-induced tumor cell genomic DNA (gDNA) or mitochondrial DNA (mtDNA) fragments release, the ability to activate the type I interferon pathway in dendritic cells (DC) or macrophages in the tumor microenvironment through dsDNA response is low, and it is difficult to trigger anti-tumor immunity.

[0005] Studies have found that anti-tumor adaptive immunity does not occur spontaneously, and its initiation, maintenance, and integration of the entire cancer-immune cycle are dominated by innate immune responses; and the lack of innate immune response in the tumor microenvironment leads to abnormal functions in key links such as tumor antigen recognition, tumor antigen processing and presentation, and communication between dendritic cells (DC) and T cells, which is one of the important reasons for the "cold" tumor phenotype. Innate immunity is an important immune protection mechanism produced by organisms against the invasion of external pathogens or internal stress stress response. It senses foreign pathogen-related or endogenous damage-associated molecular patterns (PAMPs or DAMPs) through pattern recognition receptors (PRRs) expressed by innate immune cells such as macrophages, thereby triggering the body's protective immune response. In the tumor microenvironment, the innate immune response plays a vital role in anti-tumor immune processes such as tumor detection, antigen presentation, initiation and maintenance of T cell activity, and the formation of immune memory.

[0006] As the main signaling pathway for sensing intracytoplasmic DNA, cytoplasmic type I interferon-dependent innate immunity mediated by the stimulator of interferon genes (STING) and the resulting adaptive immune response are considered to be the main reasons for the immune effects or remote effects of radiotherapy. In the upstream DNA damage release and perception link, under the action of high-energy radiation, the DNA in the nucleus or mitochondria of tumor cells is broken and released into the cytoplasm or taken up by immune cells, etc., and is captured by the dsDNA receptor cyclic GMP-AMP Synthase (cGAS) in the cytoplasm to synthesize STING's natural ligand cyclic guanosine monophosphate (cGAMP); in the middle interferon release link, cGAMP activates STING multimerization to recruit TBK1 (TANK-binding kinase 1), TBK1 phosphorylates itself and STING, and then recruits and phosphorylates interferon regulatory factor 3 (Interferon Regulatory Facto r 3, IRF3), and the phosphorylated IRF3 dimer enters the nucleus to induce type I interferon release; in the terminal immune activation link, type I interferon promotes dendritic cells (DC), natural killer cells (NK), CD8 + The maturation, infiltration and activation of T cells trigger innate and adaptive immune responses and promote tumor killing.

[0007] The release of type I interferon after radiotherapy mainly includes two key stages: DNA damage release and perception, and STING activation-type I interferon release. In the early stage of DNA damage release and perception, the strong DNA damage repair ability of tumor cells reduces the generation of dsDNA caused by damage, and the lack of STING stimulatory factors leads to the obstruction of type I interferon release. There have been a large number of research reports on the mechanism and release of DNA damage repair. Although the research is mainly aimed at the direct tumor killing effect caused by DNA damage, the various treatment methods developed by related research institutes to block DNA damage repair will help solve the immunosuppression barriers in this link.

[0008] The presence of inhibitory factors in the STING activation-interferon release link will result in the inability to stably trigger type I interferon release even if radiotherapy provides sufficient dsDNA. Therefore, compared with solving the problem of DNA damage repair, how to eliminate the immunosuppression in this link is particularly important. Currently, there are few reports on such studies after radiotherapy, but some information has been revealed in the study of the STING signaling pathway. On the one hand, STING-mediated type I interferon release is a short-term response. In susceptible cells such as immune cells, after the STING pathway is activated, it will quickly trigger negative feedback regulation to inhibit the continued occurrence of immune response. On the other hand, upstream of STING, it has been found that TREX1 can reduce cGAS detection of tumors by degrading tumor-derived DNA, while ENPP1 can degrade cGAMP and reduce the level of STING activation. In summary, it shows that the stress inhibitory factors that may exist in immune cells that affect the release of type I interferon are the main reason for their low dsDNA response. It is precisely because of the presence of these immunosuppressive factors that the dsDNA-cGAS-STING signaling pathway is disabled, the ability to release type I interferon to the tumor microenvironment is limited, and the immune response is suppressed from the source. Analyzing the intrinsic mechanism of the inability of STING to activate type I interferon release will help to fully elucidate the core causes of immunosuppression after radiotherapy and provide a scientific basis for stably triggering the remote effects of radiotherapy. Therefore, it has become a cutting-edge key scientific issue and research difficulty in this field. Summary of the invention

[0009] The purpose of the present invention is to solve the problems existing in the prior art, thereby providing the use of USP1 inhibitors in the preparation of drugs for enhancing STING-mediated anti-tumor immunity. By utilizing USP1 inhibitors, the activation of the STING signaling pathway can be significantly activated, and the anti-tumor immune effect mediated by STING can be enhanced, which provides a clear scientific basis and direction for enhancing the anti-tumor therapeutic effect after radiotherapy, and has important clinical significance.

[0010] In order to solve the above technical problems, the present invention is implemented through the following technical solutions.

[0011] In a first aspect, the present invention provides use of a USP1 inhibitor in the preparation of a drug for enhancing STING-mediated anti-tumor immunity.

[0012] Preferably, the USP1 inhibitor is selected from one or more of small molecule compounds, shRNA, sgRNA, and siRNA designed based on USP1.

[0013] Preferably, the small molecule compound is selected from one or more of ML323 (CAS: 1572414-83-5), SJB2-043 (CAS: 63388-44-3), SJB3-019A (CAS: 2070015-29-9), KSQ-4279 (CAS: 2446480-97-1), C527 (CAS: 192718-06-2), and I-138 (CAS: 2098211-50-6).

[0014] The second aspect of the present invention provides the use of USP1 inhibitors in the preparation of drugs for improving the immune effect after tumor radiotherapy.

[0015] Preferably, the USP1 inhibitor is selected from one or more of small molecule compounds, shRNA, sgRNA, and siRNA designed based on USP1.

[0016] Preferably, the small molecule compound is selected from one or more of ML323, SJB2-043, SJB3-019A, KSQ-4279, C527, and I-138.

[0017] Preferably, the immune effect is specifically an immune effect related to the activation of the STING signaling pathway. Radiotherapy is one of the means of activating the STING signaling pathway in tumors, and accordingly, USP1 inhibitors can enhance the tumor therapeutic activity mediated by the STING signaling pathway after radiotherapy.

[0018] Preferably, the STING signaling pathway is a dsDNA-cGAS-STING-TBK1-IRF3 signaling pathway.

[0019] A third aspect of the present invention provides the use of a USP1 inhibitor in the preparation of a medicament for enhancing the therapeutic activity of a STING agonist.

[0020] Preferably, the USP1 inhibitor is selected from one or more of small molecule compounds, shRNA, sgRNA, and siRNA designed based on USP1.

[0021] Preferably, the small molecule compound is selected from one or more of ML323, SJB2-043, SJB3-019A, KSQ-4279, C527, and I-138.

[0022] Preferably, the STING agonist is selected from one or more of cGAMP (CAS: 1441190-66-4), diABZI (CAS: 2138299-33-7), MSA2 (CAS: 129425-81-6), S-cddA (CAS: 2447159-29-5), double-stranded DNA-ISD90, and DMXAA (CAS: 117570-53-3).

[0023] Preferably, the therapeutic activity is tumor therapeutic activity.

[0024] Preferably, the tumor therapeutic activity is tumor therapeutic activity after radiotherapy.

[0025] A fourth aspect of the present invention provides a pharmaceutical composition for enhancing anti-tumor immunity, comprising a USP1 inhibitor and a STING agonist.

[0026] Preferably, the USP1 inhibitor is selected from one or more of small molecule compounds, shRNA, sgRNA, and siRNA designed based on USP1.

[0027] Preferably, the small molecule compound is selected from one or more of ML323, SJB2-043, SJB3-019A, KSQ-4279, C527, and I-138.

[0028] Preferably, the STING agonist is selected from one or more of cGAMP, diABZI, MSA2, S-cddA, double-stranded DNA-ISD90, and DMXAA.

[0029] Preferably, the pharmaceutical composition optionally includes a pharmaceutically acceptable carrier.

[0030] Preferably, the pharmaceutically acceptable carrier is selected from one or more of a filler, a disintegrant, a lubricant, a binder, a preservative, an antioxidant, a chelating agent, a colorant, a flavoring agent, an aromatic agent, and a solvent.

[0031] The fifth aspect of the present invention provides the use of a USP1 inhibitor in the preparation of a product for promoting the release of type I interferon.

[0032] Preferably, the type I interferon is selected from one or more of INFα, INFβ, and INFκ.

[0033] Preferably, the USP1 inhibitor is selected from one or more of small molecule compounds, shRNA, sgRNA, and siRNA designed based on USP1.

[0034] Preferably, the small molecule compound is selected from one or more of ML323, SJB2-043, SJB3-019A, KSQ-4279, C527, and I-138.

[0035] A sixth aspect of the present invention provides use of a USP1 inhibitor in the preparation of a drug for promoting activation of the STING signaling pathway.

[0036] Preferably, the USP1 inhibitor is selected from one or more of small molecule compounds, shRNA, sgRNA, and siRNA designed based on USP1.

[0037] Preferably, the small molecule compound is selected from one or more of ML323, SJB2-043, SJB3-019A, KSQ-4279, C527, and I-138.

[0038] Preferably, the STING signaling pathway is a dsDNA-cGAS-STING-TBK1-IRF3 signaling pathway.

[0039] It should be understood that, in the context of the present invention, unless otherwise specified, the USP1 inhibitor refers to a substance that can specifically inhibit the activity and / or expression level of USP1. A person skilled in the art can synthesize the relevant small molecule USP1 inhibitors commercially available or by themselves according to actual needs, or can design and synthesize nucleic acids or proteins that can inhibit the activity of USP1 by molecular biological means, as long as the level and / or activity of USP1 can be reduced. The small molecule compounds such as ML323, SJB2-043, SJB3-019A, KSQ-4279, C527, I-138 listed in the context of the present invention are all types of USP1 inhibitors commonly used in the art, which can specifically inhibit the activity of USP1 and / or reduce its expression level. A person skilled in the art can clearly understand that the selection of the above-mentioned specific USP1 inhibitors is only for the purpose of demonstrating the technical scheme of the present invention, so that the person skilled in the art can more fully and completely understand the basic inventive concept of the present invention, and the specific USP1 inhibitors listed are not intended to limit the technical scheme and protection scope of the present invention. The basic concept and main contribution of the present invention is to clarify the effect of USP1 inhibitors on enhancing the anti-tumor immunity mediated by STING, that is, as long as USP1 can be inhibited, the STING-mediated anti-tumor immunity effect can be enhanced. Therefore, in addition to the specific USP1 inhibitors listed in the present invention, those skilled in the art will know that any other ingredients that can inhibit the activity and / or expression level of USP1 can also achieve the enhancement of the STING-mediated anti-tumor immunity effect.

[0040] Existing studies have found that after the synthetic cGAMP-type STING agonist was injected into the transplanted tumor, the lung metastases disappeared along with the transplanted tumor, proving that activating the Sting pathway can initiate adaptive immunity by triggering a cascade reaction to produce anti-tumor immune memory and produce a remote therapeutic effect. Nevertheless, due to the systemic distribution characteristics of immune cells, the use of STING agonists may cause systemic immune side effects, so most current STING agonists have to be used by intratumoral injection. As an important local treatment method, radiotherapy has obvious advantages in the process of cGA S-STING activation. It can achieve precise coverage of the tumor area while avoiding the occurrence of systemic side effects, so there is no need to use STING agonists that may cause systemic adverse reactions.

[0041] In theory, DNA damage caused by radiotherapy can achieve post-radiotherapy immune activation or abscopal effects through the above-mentioned dsDNA-cGAS-STING signaling pathway, but in clinical practice, cases that can produce systemic immune effects are extremely rare. This is because under tumor pathological conditions, the dsDNA-cGAS-STING immune pathway is dysregulated, resulting in the inhibition of type I interferon release. Therefore, to stably trigger the immune response to radiotherapy, it is necessary to overcome the inhibitory factors in the three links of the upstream, midstream and downstream of the dsDNA-cGAS-STING signaling pathway in a targeted manner, and the analysis of related mechanisms is indispensable. However, current research on how to trigger the abscopal effect of radiotherapy mainly focuses on the terminal immune response link after the release of type I interferon. For example, the activation of immune signals after radiotherapy can induce the expression of immune checkpoints and inhibitory factors such as cytokine TGF-β1, and a variety of clinical trials such as radiotherapy combined with immune checkpoint inhibitors and TGF-β1 antibodies have also achieved positive results. Despite this, radiotherapy combined with immunotherapy can only produce clear effects in "hot tumors" with active immune signals, but it is not effective in "cold tumors" with inactive immune signals. Logically, the lack of immune response after radiotherapy may be caused by late immunosuppressive factors such as immune checkpoints, but it may also be due to the blockage of upstream type I interferon release, resulting in the failure to activate the immune pathway. Therefore, triggering the release of type I interferon is particularly important for achieving immune activation in tumor tissues.

[0042] USP1 (Ubiquitin carboxyl-terminal hydrolase 1) is a member of the ubiquitin-specific level enzyme family and belongs to the sulfhydryl hydrolase class. USP1 can stabilize DNA-binding inhibitory proteins (ID1 / ID2 / ID3) by deubiquitinating and regulate DNA damage repair by cleaving the monoubiquitination of FANCD2 and PCNA. In addition, USP1 can also regulate processes such as tumor progression and chemotherapy resistance by maintaining the homeostasis of ULK1, MAX, MAST1 and TAZ by deubiquitinating. However, the regulatory mechanism of USP1 on the dsDNA-cGAS-STING-IRF3 signaling pathway has not yet been revealed.

[0043] In this regard, the present invention has conducted a large number of studies, based on the basic research ideas of chemical intervention phenotype-active compound discovery-pathological / pharmacological mechanism, and carried out in-depth and systematic exploration of the key factors affecting the tumor microenvironment. More than 1,000 active molecule libraries with different structures, including deubiquitinating enzymes (DUBs), kinases (Kinases), phosphodiesterases (PDEs) and other target inhibitors, were screened in two types of schemes. One was radiotherapy-related in vitro co-incubation experiment screening, which was based on the establishment of an interactive relationship between irradiated tumor cells and dendritic cells or fibroblasts in the tumor microenvironment, and the activation of the type I interferon pathway after THP1 cells took up dsDNA secreted by tumor cells; the second was to directly use STING agonists to examine the ability of various active molecules to synergistically activate STING. The results showed that USP1 inhibitors showed excellent activity in both screening schemes, and could significantly enhance the ISG response in dendritic cells or fibroblasts. It was also verified in DC2.4 cells that knocking out USP1 could significantly enhance the responsiveness of cells to dsDNA or STING agonists, while the synergistic effect of USP1 inhibitors was lost. It can be seen that deubiquitination regulation mediated by USP1 is one of the key factors in inhibiting the type I interferon signal response in immune cells.

[0044] In general, the present invention found that inhibiting the deubiquitinase USP1 can greatly enhance the response of DC and other immune cells to dsDNA, effectively improve the activation of the type I interferon pathway mediated by STING, and clarify that USP1 mediates the process of STING's reverse transport from the Golgi apparatus to the endoplasmic reticulum through deubiquitination regulation, thereby hindering the activation of STING. This mechanism is completely different from the IRF3 activation link affected by USP14. The present invention thoroughly reveals the mechanism of action of USP1, and evaluates the important role of USP1 inhibitors in enhancing anti-tumor immunity after radiotherapy in cell and animal models, providing a necessary and solid foundation for the development of radiotherapy treatment plans and tumor immunotherapy drugs with innovative mechanisms of action, and providing sufficient scientific basis for the realization of clinical transformation, which has important scientific significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 This is a schematic diagram showing that the USP1 inhibitor ML323 can synergistically promote the secretion of IF N-β1 in BMDCs in a co-incubation system.

[0046] Figure 2 Schematic diagram of the effect of USP1 inhibitor ML323 on the secretion of IFN-β1 in DC2.4, L929, and RAW264.7 cells in the co-incubation system (H22).

[0047] Figure 3 Schematic diagram of the effect of USP1 inhibitor ML323 on the expression of IFN-β1 in DC2.4, L929, and RAW264.7 cells in the co-incubation system (H22).

[0048] Figure 4 Schematic diagram of the effect of USP1 inhibitor ML323 on IFN-β1 in DC2.4, L929, and RAW264.7 cells in the co-incubation system (CT26).

[0049] Figure 5 This is a schematic diagram of the effects of ML323 on IFN-β1 and CXCL-10 in tumor-transplanted mice.

[0050] Figure 6 Schematic diagram of the effect of USP1 inhibitor SJB2-043 on IFN-β1 in the co-incubation system (H22).

[0051] Figure 7 Schematic diagram of the effects of SJB2-043 on IFN-β1 and CXCL-10 in tumor-transplanted mice.

[0052] Figure 8 Schematic diagram of the effect of USP1 inhibitor alone on tumor cells.

[0053] Fig. 9 Schematic diagram of the results showing that pre-incubation of ML323 can significantly enhance the production of IFN-β1 by DC2.4 and L929 stimulated by LSD90.

[0054] Fig.10 Schematic diagram of the effect of ML323 on dsDNA during co-incubation.

[0055] Fig.11 Schematic diagram of the effect of ML323 on the level of 2', 3'-cGAMP in the cytoplasm during co-incubation.

[0056] Fig.12 This is a schematic diagram showing that ML323 can exert excellent synergistic effects in DC2.4, L929, and RAW264.7 cells when the STING signaling pathway is activated.

[0057] Fig.13 This is a schematic diagram of the effect of ML323 on IFN-β1 expression in DC2.4 and L929 cells under the action of S-cddA.

[0058] Fig.14 This is a schematic diagram of the effects of STING inhibitors on the synergistic effect between ML323 and ISD90.

[0059] Fig.15 This is a schematic diagram of the synergistic effect of STING inhibitor on ML323 co-incubation.

[0060] Fig.16 Schematic diagram of the effect of USP1 inhibitors on synergy with STING agonists.

[0061] Fig.17 This is a schematic diagram of the effect of time on the synergistic effect of ML323 and S-cddA in DC2.4 cells.

[0062] Fig.18 This is a schematic diagram of the results of the synergistic effect of ML323 and S-cddA in DC2.4 cells being affected by the concentration of ML323.

[0063] Fig.19 This is a schematic diagram of the effect of time on the synergistic effect of ML323 and S-cddA in L929 cells.

[0064] Fig. 20 This is a schematic diagram of the results showing that the synergistic effect of ML323 and S-cddA in L929 cells is affected by the concentration of ML323.

[0065] Fig.21This is a schematic diagram of the effect of time on the synergistic effect of ML323 and S-cddA in RAW264.7 cells.

[0066] Fig. 22 This is a schematic diagram of the results showing that the synergistic effect of ML323 and S-cddA in RAW264.7 cells is affected by the concentration of ML323.

[0067] Fig.23 This is a schematic diagram of the results of the synergistic effect of ML323 and S-cddA in DC2.4 cells being affected by the concentration of S-cddA.

[0068] Fig.24 This is a schematic diagram of the results showing that the synergistic effect of ML323 and S-cddA in L929 cells is affected by the concentration of S-cddA.

[0069] Fig.25 This is a schematic diagram of the results showing that the synergistic effect of ML323 and S-cddA in RAW264.7 cells is affected by the concentration of S-cd dA.

[0070] Fig.26 This is a schematic diagram of the effects of USP1 inhibitors combined with high-dose radiotherapy on tumor growth rate and volume in vivo. DETAILED DESCRIPTION

[0071] In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0072] Unless otherwise specified, the cell lines listed in the context of the present invention, including DC2.4 (mouse dendritic cells), RAW264.7 (mouse mononuclear macrophage leukemia cells), THP 1 (human mononuclear leukemia cells), H22, BMDC, etc., were cultured according to the existing technology, and all cell lines were identified by short tandem repeat analysis of China Center for Type Culture Collection (Wuhan), and the presence of mycoplasma contamination was verified using a PCR detection kit (Shanghai Biothrive Sci), and were frozen in liquid nitrogen and used for subsequent experiments. The reagents used in the present invention are all commercially available, wherein the STING signaling pathway agonist is selected from SATE-cddA (S-cddA, CAS: 2447159-29-5), double-stranded DNA-ISD90, etc., which are used to stimulate and simulate the activation of the STING signaling pathway; in order to facilitate the display of the technical scheme and technical concept of the present invention, the experiments on USP1 inhibitors involved in the context of the present invention are all carried out using ML323, SJB2-043, SJB3-019A, KSQ-4279, C527 and I-138, etc., and those skilled in the art can know that other components with inhibitory activity on USP1 have the same or similar effects, and are specifically verified by the methods mentioned in the art or the present invention. The enumeration and selection of USP1 inhibitors in the present invention are not intended to limit the present invention. The experimental methods used in the present invention, such as molecular biology experiments, cell experiments, animal experiments, etc., are all conventional methods and techniques in the art. Representative results selected from repeated biological experiments are presented in the context figures, and the data are presented as mean±SD and mean±SEM as specified in the figure. All in vitro experiments were repeated at least three times. Data were analyzed using GraphPad Prism 8.0 or SPSS22.0 software. Conventional medical statistical methods such as t-test, chi-square test, and analysis of variance were used to compare the mean differences between two or more groups. p < 0.05 was considered a significant difference.

[0073] Example 1

[0074] First, from the basic research ideas of chemical intervention phenotype-active compound discovery-pathological / pharmacological mechanism, we carried out in-depth and systematic exploration of the key factors affecting the tumor microenvironment, and screened more than 1,000 active molecular libraries with different structures, including deubiquitinating enzymes (DUBs), kinases (Kinases), phosphodiesterases (PDEs) and other target inhibitors, for two types of schemes. The first is the radiotherapy-related in vitro co-incubation experiment screening, which is based on the establishment of an interactive relationship between irradiated tumor cells and THP1 cells, and the investigation of the activation of the type I interferon pathway after DC2.4 cells take up dsDNA secreted by tumor cells; the second is to directly use STING agonists to investigate the ability of various active molecules to synergistically activate STING. The results showed that the USP1 inhibitor ML323 (CAS: 1572414-83-5) showed excellent activity in both screening schemes and could significantly enhance the ISG response in DC2.4 cells.

[0075] Subsequently, the USP1 inhibitor ML323 was co-incubated with H22, BMDCs, etc. to study its effect on radiotherapy-induced immune activation. Specifically, after H22 was irradiated with a dose of 40Gy, H22 was co-incubated with BMDCs, and the supernatant was taken for Elisa detection of secreted IFN-β1, and BMDCs were subjected to qPCR detection of IFN-β1 expression. The results showed that the USP1 inhibitor ML323 (5μM) was able to exert an excellent synergistic effect with radiotherapy when co-incubated with H22 and BMCDs cells; the IFN-β1 Elisa kit was used to detect the secreted IFN-β1 produced by BMDCs, and the qPCR detection of BMDCs IFN-β1 gene expression indicated that the USP1 inhibitor ML323 could synergistically promote the secretion (****p<0.0001) and expression (****p<0.0001) of IFN-β in BMDCs under the co-incubation system (see Figure 1 ).

[0076] Referring to the above experimental method, ML323 was co-incubated with H22 cells in DC2.4, L929, and RAW264.7 cells, and the secretion of IFN-β1 was detected. The results showed that ML323 could promote the secretion of IFN-β1 (***p<0.001, ****p<0.0001) (see Figure 2 );qPCR detection of IFN-β1 gene expression in BMDCs showed that ML323 could promote the expression of IFN-β1 in DC2.4, L929, and RAW264.7 cells (see Figure 3). Subsequently, ML323 was co-incubated with CT26 cells in DC2.4, L929, and RAW264.7 cells, and the secretion of IFN-β1 was detected. The results were similar to those above, that is, ML323 could also promote the secretion of IFN-β1 (***p<0.001, ****p<0.0001) (see Figure 4 ).

[0077] Furthermore, CT26 was used to perform tumor xenografts in Balb / c mice. After the tumors were formed, the tumors were taken for radiotherapy and the secretion of IFN-β1 and CXCL-10 was detected. Specifically, CT26 cells were cultured in the axilla of Balb / c mice (100W / mouse). After about a week of tumor formation, the complete tumor was taken out, and the tumor was ground and enzymatically hydrolyzed for adherent culture; then radiation and radiation combined with USP1 inhibitor ML323 (5μM) were performed (irradiation dose 8Gy, continuous irradiation for three days). 24 hours after the completion of radiotherapy, the supernatant was taken for Elisa to detect the secretion of IFN-β1 and CXCL 10. The results showed that ML323 can synergistically promote the secretion of IFN-β1 and CXCL-10 in mouse tumor tissues (see Figure 5 ).

[0078] In addition to ML323, another USP1 inhibitor SJB2-043 (CAS: 63388-44-3) was selected to repeat the above experiment. The results showed that SJB2-043 can also exert a certain synergistic effect when DC2.4, L929, RAW264.7 and H22 are co-incubated. The IFN-β1 Elisa kit detects the secreted IFN-β1 produced by BMDCs, indicating that SJB2-043 can synergistically promote the secretion of IFN-β by BMDCs in the co-incubation system (*p < 0.05, **p < 0.01) (see Figure 6 ); In vivo experimental results showed that after using CT26 cells to form tumors in Balb / c mice, radiotherapy was performed and the secretion of IFN-β1 and CXCL-10 was detected. It was found that SJB2-043 could synergistically promote the secretion of IFN-β1 and CXCL10 in mouse tumor tissues (**p<0.05, ***p<0.001) (see Figure 7 These results together suggest that USP1 inhibitors can synergistically promote immune activation induced by radiotherapy.

[0079] Example 2

[0080] In order to clarify the direct effect of USP1 inhibitors on tumor cell radiotherapy, H22 and CT26 cells were pretreated with ML323 at corresponding concentrations, and then irradiated. After 2-4 hours, the cells were collected to extract RNA, and the mRNA levels of factors such as IFN-β1 were detected by qPCR. The results showed that in the absence of immune cells, it was difficult to activate the STING signaling pathway and the expression and secretion of IFN-β1 in tumor cells after radiotherapy when USP1 inhibitors were used alone to treat tumor cells. (See Figure 8 ), which means that USP1 inhibitors are mainly used to enhance the activity of the STING pathway in immune cells and have little effect on tumor cells. After radiotherapy of tumors in vivo, tumor cells serve as donors of substances such as dsDNA that activate immune cells. Under the action of USP1 inhibitors, the immunogenicity of related immune cells in the tumor can be effectively enhanced.

[0081] ML323 was pre-incubated in DC2.4 and L929 cells, and H22 cells (10 7 / well), and after irradiation treatment (irradiation dose 40Gy), H22 cells were resuspended in medium containing DUB inhibitors and added to adherent cultured BMDCs / DC2.4 / L929 / RAW 264.7 (cell number 10 7 / well), after 12h of co-culture, the supernatant was taken for Elisa to detect the secretion of IFN-β1 and CXCL10; after washing H22 cells, RNA of BMDCs was extracted, and the expression of IFN-β1 and CXCL10 was detected by qPCR. The results showed that ML323 pre-incubation treatment could significantly increase the production of IFN-β1 by DC2.4 and L929 stimulated by double-stranded DNA-ISD90 (see Fig. 9 ). The detection of dsDNA and cGAMP during co-incubation showed that ML323 did not affect the production of dsDNA during co-incubation and the level of 2', 3'-cGAMP in the cytoplasm (****p<0.0001) (see Figure 10-11 ).

[0082] Subsequently, 2', 3'-cGAMP (100nM, 2h) or S-cddA (100nM, 2h) was used as a STING agonist to treat DC2.4, L929, and RAW264.7 cells, respectively. After DC2.4 / L929 / RAW 264.7 cells were plated and adhered (cell number 50w), cGAMP (100nM) / S-cddA (100nM), cGAMP (100nM) + ML323 (5μM) / S-cddA (100nM) + ML323 (5μM) were added for stimulation, RNA was extracted at 2h, and the expression of IFN-β1 and CXCL10 was detected by qPCR. The results showed that when the STING signaling pathway was activated, ML323 could exert excellent synergistic effects in DC2.4, L929, and RAW264.7 cells (see Fig.12 At the same time, when S-cddA (100nM, 2h) was used as the STI NG agonist, ML323 could significantly stimulate the expression of IFN-β1 in DC2.4 and L929 cells in a short period of time (see Fig.13 ), EC of ML323 promoting IFNβ1 in DC2.4 and L929 cells 50 They are 3.625μM and 9.539μM respectively.

[0083] In addition to 2', 3'-cGAMP and S-cddA, the above experiment was repeated using another STING agonist, ISD90. The results showed that ML323 could exert an excellent synergistic effect after pre-incubation in DC2.4 and L929 with ISD90 as an agonist. The EC of ML323 in DC2.4 and L929 for promoting IFNβ1 was 50 5.188 μM and 4.064 μM respectively.

[0084] DC2.4 and L929 cells were treated with STING inhibitor H151, and DC2.4 / L929 cells were plated and adhered (cell number 50w). H151 (5μM) was used, and DMSO was incubated for 4 hours. ISD90 was added for stimulation, and RNA was extracted at 2 hours. The expression of IFN-β1 and CXCL10 was detected by qPCR. It was found that the synergistic effect of ML323 and ISD 90 in DC2.4 and L929 disappeared (****p<0.0001) (see Fig.14 ); At the same time, it was found that the synergistic effect of ML323 in DC2.4 and L929 cells was eliminated (*p<0.05, ****p<0.0001) (see Fig.15 ).

[0085] Further, the effect of USP1 inhibitor concentration on synergistic effect with STING agonist was studied. After L929 cells were plated and adhered (cell number 50w), one group was stimulated by adding ML323 + DMXAA (STING agonist) with a concentration gradient (0 / 2.5 / 5 / 10 / 25 / 50μM), and the other group was stimulated by adding S-cddA (100nM), S-cddA (100nM) + SJB2-043 with a concentration gradient (1 / 2.5 / 5 / 10 / 20μM); RNA was extracted at 2h, and the expression of IFN-β1 was detected by qPCR. The results showed that USP1 inhibitor ML323 and DMXAA, SJB2-043 and S-cddA can all exert synergistic effects, and the synergistic effect increases with the increase of DMXAA or SJB2-043 concentration, and is concentration-dependent (see Fig.16 ). The above results collectively indicate that the synergistic effect of USP1 inhibitors is cGAS-STING pathway-dependent and concentration-dependent.

[0086] Example 3

[0087] In order to further study the regulatory effect of USP1 inhibitor on cGAS-STING signaling pathway, S-cddA was used as an agonist in DC2.4 cells. The synergistic effect of ML323 and S-cddA was shown to change over time. After DC2.4 cells were plated and adhered to the wall (cell number 100w), S-cddA (100nM) and S-cddA (100nM) + ML323 (5μM) were added. Proteins were extracted at 0 / 2 / 4 / 6 / 8 / 10h, and the expression of P-STING and P-TBK1 proteins was detected by Weston blot method. The results showed that the levels of P-STING and P-TBK1 gradually increased (see Fig.17 ); At the same time, the synergistic effect increased with the increase of ML323 concentration, and the levels of P-STING and P-TBK1 were positively correlated with the ML323 concentration (see Fig.18 ).

[0088] Subsequently, the above experiment was repeated in L929 and RAW264.7 cells, and similar results were observed, that is, with S-cddA (100nM) as an agonist, ML323 and S-cddA exerted a synergistic effect, which was manifested as the gradual increase in P-STING and P-TBK1 levels over time; at the same time, the synergistic effect increased with the increase in ML323 concentration, and the P-STING and P-TBK1 levels were positively correlated with the ML323 concentration (see Figure 19-22 ).

[0089] Furthermore, the synergistic effect of ML323 and S-cddA was studied in DC2.4, L929, and RAW264.7 at a fixed concentration of ML323 (5 μM). The results showed that the synergistic effect increased with the increase of S-cddA concentration, and the levels of P-STING and PTBK1 were positively correlated with the S-cddA concentration (see Figure 23-25 ).

[0090] Example 4

[0091] The therapeutic activity of USP1 inhibitor combined with radiotherapy in vivo was studied. The specific steps were as follows: 4-5 week old female Balb / C mice were implanted with bilateral axillary tumors at 100w / mouse. After one week, the mice were divided into blank control group, ML323 group, radiotherapy group, and radiotherapy + ML323 group. The ML323 group and the radiotherapy + ML323 group were given ML323 (10mg / kg) for 7 days starting from the day before the start of radiotherapy. From the 11th day, the radiotherapy group and the radiotherapy + ML323 group started radiotherapy at the same time, and the radiotherapy dose was 8Gy×5 days. After the end of radiotherapy, the tumor volume was continuously recorded. The mice in the blank control group and ML323 group were killed on the 15th day, and the mice in the radiotherapy group and the radiotherapy + ML323 group were killed on the 23rd day. The tumors were removed, fixed with paraformaldehyde, and sliced ​​for HE and IHC staining analysis. The results showed that radiotherapy and radiotherapy combined with ML323 treatment groups could activate the immunity of mice under high-dose irradiation and have a control effect on tumors. Compared with the radiotherapy group, the ML323 combined treatment group was able to control tumor growth in a very short period of time, and after the end of radiotherapy, tumor control was still better than that of the radiotherapy group (see Fig.26 ). It is worth noting that the control of non-irradiated distant tumors after combined with ML323 was also significantly better than that of the radiotherapy group alone, which shows that ML323 can significantly enhance the immune effect after radiotherapy.

[0092] It can be clearly seen from the above that deubiquitination regulation mediated by USP1 is one of the key factors in inhibiting the response of type I interferon signals in immune cells. USP1 mediates the stress-inhibiting factors of type I interferon production in susceptible cells such as immune cells, thereby hindering the failure of anti-tumor immune activation after radiotherapy. Mechanism studies have shown that USP1 can quickly sense the signals of STING aggregation and transport, relieve its ubiquitination state, and thus interrupt the continuous activation of STING signals. In general, the present invention has found that inhibiting the deubiquitinating enzyme USP1 can greatly enhance the response of immune cells such as DC to dsDNA, effectively improve the activation degree of type I interferon pathway mediated by STING, and clarify the mechanism of action of USP1. The present invention thoroughly reveals the mechanism of action of USP1, and evaluates the important role of USP1 inhibitors in enhancing anti-tumor immunity after radiotherapy in cell and animal models, providing a necessary and solid foundation for the development of radiotherapy treatment schemes and tumor immunotherapy drugs with innovative mechanisms of action, and providing sufficient scientific basis for the realization of clinical transformation, which has important scientific significance.

[0093] The above specific implementation method part specifically introduces the analytical method involved in the present invention. It should be noted that the above introduction is only to help those skilled in the art better understand the method and ideas of the present invention, rather than limiting the relevant content. Without departing from the principle of the present invention, those skilled in the art may also make appropriate adjustments or modifications to the present invention, and the above adjustments and modifications shall also fall within the scope of protection of the present invention.

Claims

1. Application of USP1 inhibitors in the preparation of drugs for enhancing STING-mediated anti-tumor immunity.

2. The use according to claim 1, characterized in that: The USP1 inhibitor is selected from one or more of small molecule compounds, shRNA, sgRNA, and siRNA designed based on USP1.

3. Application of USP1 inhibitors in the preparation of drugs for improving the immune effect after tumor radiotherapy.

4. The use according to claim 3, characterized in that: The USP1 inhibitor is selected from one or more of small molecule compounds, shRNA, sgRNA, and siRNA designed based on USP1.

5. The use according to claim 3, characterized in that: The immune effect is specifically an immune effect associated with activation of the STING signaling pathway.

6. Application of USP1 inhibitors in the preparation of drugs for enhancing the therapeutic activity of STING agonists.

7. The use according to claim 6, characterized in that: The USP1 inhibitor is selected from one or more of small molecule compounds, shRNA, sgRNA, and siRNA designed based on USP1.

8. A pharmaceutical composition for enhancing anti-tumor immunity, characterized in that: Including USP1 inhibitors and STING agonists.

9. The pharmaceutical composition according to claim 8, characterized in that The USP1 inhibitor is selected from one or more of small molecule compounds, shRNA, sgRNA, and siRNA designed based on USP1.

10. Application of USP1 inhibitors in the preparation of drugs that promote activation of the STING signaling pathway.

Citation Information

Patent Citations

  • Biologically related substances modified by multifunctional H-type polyethylene glycol derivative

    CN104530413A

  • Small molecule inhibitors of USP1 deubiquitinating enzyme activity

    US20130253005A1

  • Methods of Treating Conditions Involving Elevated Inflammatory Response

    US20190167710A1

  • Methods of treating cancers

    US20210186964A1

  • Compositions for treating breast cancer

    WO2018148598A1